Results tagged “Masonic Cancer Center News”
"Mutant variants of human cells": the phrase conjures up images of a bad sci-fi movie. But Reuben Harris, Ph.D., has been studying cell mutations for more than 20 years, and his recent finding is more akin to an Oscar-winning blockbuster. So remarkable is his work that the prestigious journal Nature in February published his discovery that a protein that occurs naturally in the body appears to be a driver for more than half of breast cancers he studied. This breakthrough could lead to new diagnostic tools and, potentially, new treatments for breast cancer.
Across the street, across the state, across the country, and across the world, members of the Masonic Cancer Center are helping people live healthier lives. Not only does the impact of our research stretch across borders and oceans, but some of our leaders are working directly with leaders in other countries to accomplish a myriad of goals — to share knowledge, to exchange ideas, and even to help meet basic needs.
Michael Verneris, M.D., senses an urgent need every time he looks into the faces of his young patients who have acute lymphoblastic leukemia at the Journey Clinic at University of Minnesota Amplatz Children's Hospital. "The need to develop new treatments, less toxic and more effective than chemotherapy, is huge," he says, "and I feel that sense of urgency every week when I sit next to a patient and have to explain that the options are slim."
It has been more than a decade since evidence first emerged linking diabetes to cancer, and what doctors have learned so far is grim: Diabetics are twice as likely to get cancer of the liver, uterus, and pancreas, and they are 20 to 50 percent more likely to develop colon and breast cancer. Women who have breast cancer are almost 50 percent more likely to die if they also have diabetes.
"There's definitely a proven connection between diabetes and cancer," says David Potter, M.D., Ph.D., a breast cancer physician and member of the Masonic Cancer Center, University of Minnesota. "But even though we've learned a lot, there's much more work to be done to get us to workable solutions to reduce cancer risk for diabetic patients."